Richter Gedeon Vegyeszeti Gyar Nyrt
LSE:0QFP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (1.2), the stock would be worth Ft4 422.46 (12% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.4 | Ft5 040 |
0%
|
| 3-Year Average | 1.2 | Ft4 422.46 |
-12%
|
| 5-Year Average | 1.2 | Ft4 422.46 |
-12%
|
| Industry Average | 340.1 | Ft1 212 984.36 |
+23 967%
|
| Country Average | 1.3 | Ft4 741.89 |
-6%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| HU |
R
|
Richter Gedeon Vegyeszeti Gyar Nyrt
LSE:0QFP
|
2.2T HUF | 1.4 | 9.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 8.9 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 3.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 2.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 3.7 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 2.9 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 2.6 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 56 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 2.7 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 1 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | -9.1 | 4 516.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 0.5 |
| Median | 1.3 |
| 70th Percentile | 1.4 |
| Max | 669.4 |
Other Multiples
Richter Gedeon Vegyeszeti Gyar Nyrt
Glance View
Richter Gedeon Vegyeszeti Gyar Nyrt., popularly known as Gedeon Richter, traces its origins to 1901, when its founder, Gedeon Richter, established a modest pharmacy on the outskirts of Budapest. With a deep passion for innovation and a forward-thinking mindset, Richter transformed his small endeavor into Hungary's pioneering pharmaceutical company. Today, Gedeon Richter stands as a significant player in the global pharmaceutical industry, excelling in the research, development, manufacturing, and marketing of a wide array of medicinal products. The company's emphasis on in-house innovation and strategic collaborations has enabled it to carve a niche in the field of women's healthcare, biotechnology, and central nervous system therapies. The heart of Gedeon Richter's operations lies in its robust research and development capabilities. By investing heavily in scientific excellence, the company has developed a diversified portfolio that includes generic and specialty pharmaceuticals, as well as original research-driven products. The company generates revenue through a network that spans more than 100 countries, with a strong presence in Europe, the Commonwealth of Independent States, and the global markets at large. By keeping its manufacturing processes vertically integrated and maintaining a comprehensive distribution network, Gedeon Richter not only ensures efficiency and cost-effectiveness, but also consistently delivers quality products to both niche markets and mass consumers. This strategic focus on sustainable growth, combined with its commitment to providing innovative healthcare solutions, reflects the synergy of past legacy with future-focused aspirations.